Cidara Therapeutics

Addressing serious fungal infections through a pipeline of innovative therapeutics

Cidara (NASDAQ: CDTX) is focusing on the discovery, development, and commercialization of therapeutics to treat serious fungal infections. The company’s pipeline is based on two core technologies: 1) “Cloudbreak”, an innovative immunotherapy approach to recruit the immune system to the sites of serious fungal infections, and 2) CD101, a next-generation echinocandin drug that enables both IV and topical formulations. Cidara was named to FierceBiotech's "Fierce 15" in 2014, and the company priced its IPO in 2015.

Status

IPO in 2015 (NASDAQ: CDTX)

Year of Investment

2014

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

San Diego, California

Frazier Team

Social Media